Nature Medicine, Published online: 09 July 2026; doi:10.1038/s41591-026-04525-0
A phase 1/2 trial of an off-the-shelf stem cell-derived dopaminergic progenitor therapy demonstrated a favorable 12-month safety profile, with no graft-related adverse events, dyskinesias or tumor formation, although risks were associated with the immunosuppression regimen.
